Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979375 | 0.97 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL3956463 | 0.95 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL3972796 | 0.95 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL3974416 | 0.95 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL3960765 | 0.87 | MEN1 (0.41) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL5717891 | 0.85 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL3960469 | 0.85 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL13842135 | 0.82 | LMNA (0.52) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3961565 | 0.82 | LMNA (0.39) | — | |
| SCHEMBL3972404 | 0.82 | SLC6A2 (0.44) | SLC6A2OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531543-B2 | Phenylpiperazine cycloalkanol derivatives and methods of their use | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1673358-A1 | PHENYLPIPERAZINE CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050143394-A1 | Phenylpiperazine cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005037808-A1 | PHENYLPIPERAZINE CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143394-A1 | Phenylpiperazine cycloalkanol derivatives and methods of their use | HTR5A, PNMT, HTR3A | SLC6A2 49/4885SLC6A4 56/4885SLC6A3 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.